576 related articles for article (PubMed ID: 27859332)
21. Plerixafor and G-CSF for autologous stem cell mobilization in patients with NHL, Hodgkin's lymphoma and multiple myeloma: results from the expanded access program.
Shaughnessy P; Uberti J; Devine S; Maziarz RT; Vose J; Micallef I; Jacobsen E; McCarty J; Stiff P; Artz A; Ball ED; Berryman R; Dugan M; Joyce R; Hsu FJ; Johns D; McSweeney P
Bone Marrow Transplant; 2013 Jun; 48(6):777-81. PubMed ID: 23178544
[TBL] [Abstract][Full Text] [Related]
22. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M
J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597
[TBL] [Abstract][Full Text] [Related]
23. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.
Attolico I; Pavone V; Ostuni A; Rossini B; Musso M; Crescimanno A; Martino M; Iacopino P; Milone G; Tedeschi P; Coluzzi S; Nuccorini R; Pascale S; Di Nardo E; Olivieri A
Biol Blood Marrow Transplant; 2012 Feb; 18(2):241-9. PubMed ID: 21791194
[TBL] [Abstract][Full Text] [Related]
24. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program.
Hübel K; Fresen MM; Salwender H; Basara N; Beier R; Theurich S; Christopeit M; Bogner C; Galm O; Hartwig R; Heits F; Lordick F; Rösler W; Wehler D; Zander AR; Albert MH; Dressler S; Ebinger M; Frickhofen N; Hertenstein B; Kiehl M; Liebler S; von Lilienfeld-Toal M; Weidmann E; Weigelt C; Lange F; Kröger N
Bone Marrow Transplant; 2011 Aug; 46(8):1045-52. PubMed ID: 20972470
[TBL] [Abstract][Full Text] [Related]
25. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
Pusic I; Jiang SY; Landua S; Uy GL; Rettig MP; Cashen AF; Westervelt P; Vij R; Abboud CN; Stockerl-Goldstein KE; Sempek DS; Smith AL; DiPersio JF
Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768
[TBL] [Abstract][Full Text] [Related]
26. The effect of mobilizing large numbers of CD34 + cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation.
Moreb JS; Lantos L; Chen F; Elliott K; Dugan J; Skarbnik AP; Kropf PL; Ward K
Transfus Apher Sci; 2023 Dec; 62(6):103787. PubMed ID: 37704508
[TBL] [Abstract][Full Text] [Related]
27. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient.
Stiff P; Micallef I; McCarthy P; Magalhaes-Silverman M; Weisdorf D; Territo M; Badel K; Calandra G
Biol Blood Marrow Transplant; 2009 Feb; 15(2):249-56. PubMed ID: 19167685
[TBL] [Abstract][Full Text] [Related]
28. Optimizing autologous stem cell collections for patients with multiple myeloma receiving G-CSF and Plerixafor: A single center project.
Javanbakht A; Stringer S; Anderson H; Hamilton E; Philip A; Waller EK; Langston AA; Joseph N; Roback JD; Schneider T; Sullivan HC; Hendrickson JE
J Clin Apher; 2024 Jun; 39(3):e22127. PubMed ID: 38803152
[TBL] [Abstract][Full Text] [Related]
29. [Efficiency and safety analysis of Plerixafor combined with granulocyte colony-stimulating factor on autologous hematopoietic stem cell mobilization in lymphoma].
Ji MM; Shen YG; Gong JC; Tang W; Xu XQ; Zheng Z; Chen SY; He Y; Zheng X; Zhao LD; Zhao WL; Wu W
Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):112-117. PubMed ID: 36948864
[No Abstract] [Full Text] [Related]
30. Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation.
Stover JT; Shaw JR; Kuchibhatla M; Horwitz ME; Engemann AM
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1290-1294. PubMed ID: 28411174
[TBL] [Abstract][Full Text] [Related]
31. Blood graft lymphocyte subsets after plerixafor injection in non-Hodgkin's lymphoma patients mobilizing poorly with chemotherapy plus granulocyte-colony-stimulating factor.
Varmavuo V; Mäntymaa P; Kuittinen T; Nousiainen T; Jantunen E
Transfusion; 2012 Aug; 52(8):1785-91. PubMed ID: 22304442
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors for re-mobilization using plerixafor and granulocyte colony-stimulating factor (G-CSF) in patients with malignant lymphoma or multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy: the Korean multicenter retrospective study.
Kim JS; Yoon DH; Park S; Yoon SS; Cho SG; Min CK; Lee JJ; Yang DH; Kwak JY; Eom HS; Kim WS; Kim H; Do YR; Moon JH; Lee J; Suh C
Ann Hematol; 2016 Mar; 95(4):603-11. PubMed ID: 26754633
[TBL] [Abstract][Full Text] [Related]
33. Plerixafor on-demand combined with chemotherapy and granulocyte colony-stimulating factor: significant improvement in peripheral blood stem cells mobilization and harvest with no increase in costs.
Milone G; Martino M; Spadaro A; Leotta S; Di Marco A; Scalzulli P; Cupri A; Di Martina V; Schinocca E; Spina E; Tripepi G
Br J Haematol; 2014 Jan; 164(1):113-23. PubMed ID: 24138497
[TBL] [Abstract][Full Text] [Related]
34. Clinical outcomes of multiple myeloma patients who undergo autologous hematopoietic stem cell transplant with G-CSF or G-CSF and plerixafor mobilized grafts.
Shah H; Kim S; Singh P; Alavi A; Ratanatharathorn V; Ayash L; Uberti J; Deol A
Am J Hematol; 2020 Feb; 95(2):198-204. PubMed ID: 31691333
[TBL] [Abstract][Full Text] [Related]
35. Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilization.
Bakeer M; Zubair AC; Roy V
Cytotherapy; 2020 Jan; 22(1):16-20. PubMed ID: 31879152
[TBL] [Abstract][Full Text] [Related]
36. Beyond CD34+ cell dose: impact of method of peripheral blood hematopoietic stem cell mobilization (granulocyte-colony-stimulating factor [G-CSF], G-CSF plus plerixafor, or cyclophosphamide G-CSF/granulocyte-macrophage [GM]-CSF) on number of colony-forming unit-GM, engraftment, and Day +100 hematopoietic graft function.
Alexander ET; Towery JA; Miller AN; Kramer C; Hogan KR; Squires JE; Stuart RK; Costa LJ
Transfusion; 2011 Sep; 51(9):1995-2000. PubMed ID: 21392017
[TBL] [Abstract][Full Text] [Related]
37. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
Russell N; Douglas K; Ho AD; Mohty M; Carlson K; Ossenkoppele GJ; Milone G; Pareja MO; Shaheen D; Willemsen A; Whitaker N; Chabannon C
Haematologica; 2013 Feb; 98(2):172-8. PubMed ID: 22983579
[TBL] [Abstract][Full Text] [Related]
38. [Effectiveness of plerixafor in patients undergoing mobilization autologous haematopoietic progenitor cell].
Ruano Camps R; Ortiz Pareja M; Vidales Mancha I; Muñoz Castillo IM; Heiniger Mazo AI
Farm Hosp; 2013; 37(4):317-21. PubMed ID: 24010693
[TBL] [Abstract][Full Text] [Related]
39. Impact of Single-Dose Plerixafor as an Adjunct to Granulocyte Colony-Stimulating Factor-Based Peripheral Blood Stem Cell Mobilization on the Graft Composition and Outcome for T Cell-Replete Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: A Comparative Study.
Jaiswal SR; Bhakuni P; Joy A; Murli N; Bharadwaj P; Zaman S; Nedunchezian M; Chakrabarti S
Biol Blood Marrow Transplant; 2018 Mar; 24(3):542-548. PubMed ID: 29191663
[TBL] [Abstract][Full Text] [Related]
40. Autologous Stem Cell Mobilization in the Age of Plerixafor.
Cooper DL; Medoff E; Patel N; Baker J; Pratt K; Foss F; Seropian SE; Perreault S; Wu Y
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):411-6. PubMed ID: 27245311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
